Medications, often seen as the prototypical “biological” intervention, rarely have the kind of specificity that is such a hallmark of the biomedical diagnostic–therapeutic strategy (55) typified by antibiotics for streptococcal pharyngitis or insulin for type I diabetes, when used in the course of management of children with neurodisability. This evidence concerns the gene INS and streptococcal pharyngitis.